Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Running, not enrolling · Phase 1

Conditions studied: Advanced or Metastatic Solid Tumors

In brief

This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4

Key facts

Study ID

NCT06781983

Run by

Innate Pharma

People needed

145

Starts

2025-01-24

Expected to finish

2029-04-01

Last updated by the study team

2026-07-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Massachusetts General Hospital - Boston — Boston, Massachusetts, United States
• John Theurer Cancer Center — Hackensack, New Jersey, United States
• Mount Sinai Tisch Cancer Center — New York, New York, United States
• NEXT Oncology - Dallas — Dallas, Texas, United States
• NEXT Oncology - Virginia — Fairfax, Virginia, United States
• Centre Léon Bérard — Lyon, France
• Gustave Roussy Cancer Institute — Villejuif, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.